Agilent Technologies announced it has extended a co-marketing agreement with MRM Proteomics Inc..
"MRM Proteomics is a pioneer in the development of mass-spec-based methods for protein quantification and a leading provider of technologies for the pharmaceutical and biotechnology industries," said Steve Fischer, market director for Agilent's Life Science Research Group. "This collaboration further reflects our commitment to building a comprehensive portfolio of quantitative proteomics solutions for those growing industries."
Proteomics is the study of the structure and function of proteins and how they interact within a complex biological system. Agilent's integrated proteomics workflow provides the industry's highest analytical performance and features unprecedented plug-and-play flexibility. Interchangeable workflows simplify setups and let researchers quickly switch between different methodologies. Offering the industry's highest sensitivity and highest throughput quantitation, the Agilent 6495 Triple Quadrupole MS/MS provides targeted MRM peptide quantitation at attomole detection levels.
The field of mass spectrometry continues to widen to meet the growing demands of fundamental proteomics research, biomarker discovery/validation and drug development. MRM Proteomics specializes in the provision of services and kits for the highly multiplexed absolute quantitation of proteins in complex biological samples, such as blood, cerebrospinal fluid and urine, through MRM-MS using isotopically labeled internal standards.
"MRM Proteomics is delighted to expand upon our complementary partnership with Agilent," said Christoph Borchers, chief scientific officer at MRM Proteomics. "Agilent is an ideal partner because of its cutting-edge and high-sensitivity mass spectrometry technologies. The company shares our focus on delivering complete turnkey solutions for targeted quantitative proteomics."